New Modalities in Knee Osteoarthritis Treatment Using Autologous Bone Marrow-Derived Mononuclear Cells

Valdis Gončars 1 , Konstantīns Kalnbērzs 1 , Ēriks Jākobsons 2 , 3 , Ieva Briede 2 , Kristaps Blūms 4 , Kristaps Ērglis 2 , Mārtiņš Ērglis 2 , Liene Patetko 2 , Indriķis Muižnieks 5  and Andrejs Ērglis 2
  • 1 Hospital for Traumatology and Orthopaedics, Rīga Stradiņš University, LV-1005, Rīga, Latvia
  • 2 Pauls Stradiņš Clinical University Hospital, University of Latvia, LV-1002, Rīga, Latvia
  • 3 Institute of Cardiology and Regenerative Medicine, University of Latvia, LV-1002, Rīga, Latvia
  • 4 University of Latvia, , LV-1586, Rīga, Latvia
  • 5 Faculty of Biology, University of Latvia, LV-1586, Riga, Latvia


The clinical effects on knee osteoarthritis (OA) symptoms and tissue structure were evaluated after bone marrow-derived mononuclear cell intraarticular injection. A group of 32 patients with 34 knee joints in stage II–III osteoarthritis were treated by intraarticular injection of mononuclear cell suspension. Clinical results were obtained by KOOS (Knee Osteoarthritis Outcome Score) and KSS (Knee Society Score) scores during a 12 months follow-up period. Radiological evaluation was performed using magnetic resonance imaging. A comparison with a control group of 28 patients treated with routinely used three hyaluronic acid intra-articular injections was made. No adverse effects were observed after the bone marrow derived mononuclear cells (BM-MNC) injection. At the end point of the follow up all score results had improved, compared to those at to the starting point. 65% of patients maintained minimal perceptible clinical improvement of the score results. The Whole Organ Magnetic Resonance Imaging Score showed improvement from 44.31 to 42.93 points (p < 0.05) during a 6–7 month period. Comparing score results to the control group, a statistically significant (p < 0.05) improvement in the KOOS pain subscale score at the 6 and 12 months was observed in the mononuclear cell group. BM-MNC injection leads to a decrease of knee OA symptoms and slows changes in structure of the degenerative joint tissue.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Caplan, A. I. (1991). Mesenchymal stem cells. J. Orthop. Res., 9 (5), 641–650.

  • Caplan, A. I. (2008). All MSCs are pericytes? Cell Stem Cell, 3 (3), 229–230.

  • Caplan, A. I., Dennis, J. E. (2006). Mesenchymal stem cells as trophic mediators. J. Cell. Biochem., 98 (5), 1076–1084.

  • Centeno, C., Pitts, J., Al-Sayegh, H., Freeman, M., Centeno, C., Pitts, J., Al-Sayegh, H., Freeman, M. (2014). Efficacy of autologous bone marrow concentrate for knee osteoarthritis with and without adipose graft. BioMed Res. Int., DOI:10.1155/2014/370621.

  • Chen, W. C. W., Park, T. S., Murray, I. R., Zimmerlin, L., Lazzari, L., Huard, J., Péault, B. (2013). Cellular kinetics of perivascular MSC precursors. Stem Cells Int., DOI:10.1155/2013/983059.

  • Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, A., Prockop, D., Horwitz, E. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy, 8 (4), 315–317.

  • Jakobsons, E., Cakstina, I., Ramata-Stunda, A., Vorobjeva, V., Biluna, L., Boroduskis, M., Erglis, K., Narbute, I., Jegere, S., Erglis, A. (2013). Bone marrow mononuclear cell separation yield in myocardium infarction, coronary disease and type 2 diabetes and dilated cardiomyopathy patient groups. Cytotherapy, 15 (4), S31.

  • Filardo, G., Di Matteo, B., Di Martino, A., Merli, M. L., Cenacchi, A., Fornasari, P., Marcacci, M., Kon, E. (2015a). Platelet-rich plasma intra-articular knee injections show no superiority versus viscosupplementation: A randomized controlled trial. Amer. J. Sports Med., 43 (7), 1575–1582.

  • Filardo, G., Kon, E., Roffi, A., Matteo, B. D., Merli, M. L., Marcacci, M. (2015b). Platelet-rich plasma: Why intra-articular? A systematic review of preclinical studies and clinical evidence on PRP for joint degeneration. Knee Surg. Sports Traumatol. Arthrosc., 23 (9), 2459–2474.

  • Filardo, G., Perdisa, F., Roffi, A., Marcacci, M., Kon, E. (2016). Stem cells in articular cartilage regeneration. J. Orthopaed. Surg. Res., 11, 42.

  • Friedenstein, A. J. (1976). Precursor cells of mechanocytes. Int. Rev. Cytol., 47, 327–359.

  • Friedenstein, A. J., Piatetzky-Shapiro, I. I., Petrakova, K. V. (1966). Osteogenesis in transplants of bone marrow cells. J. Embryol. Experim. Morphol., 16 (3), 381–390.

  • Gobbi, A., Karnatzikos, G., Sankineani, S. R. (2014). One-step surgery with multipotent stem cells for the treatment of large full-thickness chondral defects of the knee. Amer. J. Sports Med., 42 (3), 648–657.

  • Gobbi, A., Whyte, G. P. (2016). One-stage cartilage repair using a hyaluronic acid-based scaffold with activated bone marrow-derived mesenchymal stem cells compared with microfracture. Amer. J. Sports Med., 44 (11), 2846–2854,

  • Gupta, P. K., Das, A. K., Chullikana, A., Majumdar, A. S. (2012). Mesenchymal stem cells for cartilage repair in osteoarthritis. Stem Cell Res. Ther., 3 (4), 25.

  • Hunter, D. J. (2015). Viscosupplementation for osteoarthritis of the knee. New Engl. J. Med., 372 (11), 1040–1047.

  • Jo, C. H., Lee, Y. G., Shin, W. H., Kim, H., Chai, J. W., Jeong, E. C., Kim, J. E., Shim, H., Shin, J. S., Shin, I. S., Ra, J. C., Oh, S., Yoon, K. S. (2014). Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: A proof-of-concept clinical trial. Stem Cells, 32 (5), 1254–1266.

  • Insall, J. N., Dorr, L. D., Scott, R. D., Scott, W. N. (1989). Rationale of the Knee Society Clinical Rating System. Clin. Orthop. Relat. Res., 248 (248), 13–14.

  • Kim, J.-D., Lee, G. W., Jung, G. H., Kim, C. K., Kim, T., Park, J. H., Cha, S. S., You, Y.-B. (2014). Clinical outcome of autologous bone marrow aspirates concentrate (BMAC) injection in degenerative arthritis of the knee. Eur. J. Orthopaed. Surg. Traumatol. Orthop. Traumatol., 24 (8), 1505–1511.

  • Koh, Y.-G., Jo, S.-B., Kwon, O.-R., Suh, D.-S., Lee, S.-W., Park, S.-H., Choi, Y.-J. (2013). Mesenchymal stem cell injections improve symptoms of knee osteoarthritis. Arthroscopy: J. Arthrosc. Rel. Surg., 29 (4), 748–755.

  • Kon, E., Filardo, G., Drobnic, M., Madry, H., Jelic, M., Dijk, N. van, Della Villa, S. (2012). Non-surgical management of early knee osteoarthritis. Knee Surg. Sports Traumatol. Arthrosc., 20 (3), 436–449.

  • Lee, S., Nardo, L., Kumar, D., Wyatt, C. R., Souza, R. B., Lynch, J., McCulloch, C. E., Majumdar, S., Lane, N. E., Link, T. M. (2015). Scoring hip osteoarthritis with MRI (SHOMRI): A whole joint osteoarthritis evaluation system. J. Magn. Res. Imag., 41(6), 1549–1557.

  • McAlindon, T. E., Bannuru, R. R., Sullivan, M. C., Arden, N. K., Berenbaum, F., Bierma-Zeinstra, S. M., Hawker, G. A., Henrotin, Y., Hunter, D. J., Kawaguchi, H., Kwoh, K., Lohmander, S., Rannou, F., Roos, E. M., Underwood, M. (2014). OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr. Cartil., 22 (3), 363–388.

  • Nakamura, N., Hui, J., Koizumi, K., Yasui, Y., Nishii, T., Lad, D., Karnatzikos, G., Gobbi, A. (2014). Stem cell therapy in cartilage repair-culture-free and cell culture-based methods. Scopus, 50 (2), 516–525.

  • Oliver, K. S., Bayes, M., Crane, D., Pathikonda, C. (2015). Clinical outcome of bone marrow concentrate in knee osteoarthritis. J. Prolother., 7, 937–946.

  • Peterfy, C. G., Guermazi, A., Zaim, S., Tirman, P. F. J., Miaux, Y., White, D., Kothari, M., Lu, Y., Fye, K., Zhao, S., Genant, H. K. (2004). Whole-organ magnetic resonance imaging score (WORMS) of the knee in osteoarthritis. Osteoarthr. Cartil., 12 (3), 177–190.

  • Roos, E. M., Lohmander, L. S. (2003). The knee injury and osteoarthritis outcome score (KOOS): From joint injury to osteoarthritis. Health Qual. Life Outcomes, 1, 64.

  • Roos, E. M., Roos, H. P., Lohmander, L. S., Ekdahl, C., Beynnon, B. D. (1998). Knee Injury and Osteoarthritis Outcome Score (KOOS) — development of a self-administered outcome measure. J. Orthopaed. Sports Phys. Ther., 28 (2), 88–96.

  • Tiel, J. van, Kotek, G., Reijman, M., Bos, P. K., Bron, E. E., Klein, S., Nasserinejad, K., Osch, G. J. V. M. van, Verhaar, J. A. N., Krestin, G. P., Weinans, H., Oei, E. H. G. (2016). Is T1ń mapping an alternative to delayed gadolinium-enhanced MR imaging of cartilage in the assessment of sulphated glycosaminoglycan content in human osteoarthritic knees? An in vivo validation study. Radiology, 279 (2), 523–531.


Journal + Issues